TNF-alpha induces changes in endothelial cell functions, such as upregulation of tissue factor, resulting in endothelial procoagulant activity which may play a role in disseminated intravascular coagulation. The procoagulant activity of TNF-alpha-stimulated endothelial cell monolayers was studied in a human ex vivo native (nonanticoagulated) blood flow system using the three thrombin inhibitors recombinant hirudin, Ro 46-6240, and heparin. Under venous blood flow conditions (shear rate 65 s-1) recombinant hirudin, Ro 46-6240, and heparin inhibited fibrin deposition on the endothelial cells by 50% at concentrations of 14, 28, and 412 ng/ml, respectively. The highest tested concentrations of the thrombin inhibitors reduced the postchamber fibrinopeptide A levels from 713 +/-69 to < 70 ng/ml. Surprisingly, even at relatively high inhibitor concentrations, some local fibrin deposits were found on TNF-alpha-stimulated cells, suggesting that some endothelial cells possess higher procoagulant activity than others. Therefore, the surface expression pattern of tissue factor, the primary initiator of coagulation in this system, was examined by immunogoldsilver staining. The results showed that the tissue factor density on the cell surface varied strongly among TNF-alpha-stimulated endothelial cells. Using TNF receptor-selective agonistic mutants of TNF-alpha, it was demonstrated further that the heterogenous surface expression of tissue factor was mediated entirely by the 55-kD TNF receptor and did not involve the 75-kD TNF receptor. We conclude that in this system […] Abstract TNF-a induces changes in endothelial cell functions, such as upregulation of tissue factor, resulting in endothelial procoagulant activity which may play a role in disseminated intravascular coagulation. The procoagulant activity of TNF-a-stimulated endothelial cell monolayers was studied in a human ex vivo native (nonanticoagulated) blood flow system using the three thrombin inhibitors recombinant hirudin, Ro 46-6240, and heparin. Under venous blood flow conditions (shear rate 65 s-') recombinant hirudin, Ro 46-6240, and heparin inhibited fibrin deposition on the endothelial cells by 50% at concentrations of 14, 28, and 412 ng/ml, respectively. The highest tested concentrations of the thrombin inhibitors reduced the postchamber fibrinopeptide A levels from 713±69 to < 70 ng/ml. Surprisingly, even at relatively high inhibitor concentrations, some local fibrin deposits were found on TNF-a-stimulated cells, suggesting that some endothelial cells possess higher procoagulant activity than others. Therefore, the surface expression pattern of tissue factor, the primary initiator ofcoagulation in this system, was examined by immunogold-silver staining. The results showed that the tissue factor density on the cell surface varied strongly among TNF-a-stimulated endothelial cells. Using TNF receptor-selective agonistic mutants ofTNFa, it was demonstrated further that the heterogenous surface expression of tissue factor was mediated entirely by the 55-kD TNF receptor and did not involve the 75-kD TNF receptor. We conclude that in this system TNF-a induces heterogenous tissue factor expression which may lead to a high local thrombin concentration, such that even in the presence ofthrombin inhibitors focal fibrin deposition occurs. (J. Clin. Invest. 1994.
Introduction
The development and cellular composition of a thrombus are governed by the local shear stress, which is low in veins and high in arteries. Shear stress differentially affects fibrin and platelet deposition on thrombogenic surfaces, such as suben-dothelium, collagen, or the extracellular matrix ofcultured endothelial cells (1) (2) (3) (4) (5) (6) (7) (8) . Increasing shear stress reduces fibrin deposition, while platelet deposition and thrombus formation increase. Moreover, it was reported recently that shear stress directly affects the activity of coagulation enzymes, as demonstrated by the shear stress-dependent increase in Factor X activation by tissue factor/Factor VIIa in an open flow system (9) (10) (11) . These studies emphasize the relevance of flow conditions in studying the processes leading to thrombosis and in examining new therapeutic approaches.
Shear stress also modulates the extrinsic activation ofcoagulation mediated by perturbed endothelial cells (12) . Normally, endothelial cells maintain an anticoagulant surface by expressing heparin-like structures (13, 14) , thrombomodulin (15, 16) , and components of the fibrinolytic system (17) and by secreting prostacyclin (18) . However, in vitro, cytokines such as TNF-a (19-21), IL-1 (22, 23) , and endotoxin (24) are known to change endothelial cells from an antihemostatic to a procoagulant state by inducing the expression of tissue factor and by modulating other cellular functions (25) . Endothelial tissue factor may play a role in disseminated intravascular coagulation as demonstrated in experimental sepsis models, such as endotoxin-treated rabbits (26) and baboons exposed to Escherichia coli (27) . In particular, TNF-a appears early in experimentally induced endotoxemia in humans (28, 29) and, hence, it might elicit a procoagulant response by endothelial cells. Endothelial cells express two TNF-a receptors, a 55-(TNFRp55)' and a 75-kD (TNFR-p75) receptor (30, 31) . It remained unknown whether one or both receptors is involved in inducing tissue factor on endothelial cells.
We showed previously that TNF-a-stimulated endothelial cells initiate the deposition of fibrin on their surface when exposed to flowing native blood and that this was entirely dependent on the expression of tissue factor (32) . This model uses human nonanticoagulated (native) blood (33) which, in contrast to citrated or heparin-treated blood, does not affect cation-dependent processes, such as blood coagulation, platelet adhesion, and platelet aggregation. This system was extended to investigate the effects of antithrombotics on endothelial cell-mediated deposition of fibrin and platelets at a shear rate of 65 s-', which is typical for flow conditions in large veins. A special mixing device was used which allowed supplementation of the native blood with an antithrombotic compound under continuous flow conditions. This report describes the effects ofrecombinant (rec.) hirudin (34) , heparin, and the selective, reversible thrombin in- hibitor Ro Fig. 1 is FCS, 50 ,g/ml endothelial cell growth factor, and 100 gg/ml heparin.
After washing with M 199/0.25% BSA, three coverslips were positioned in three parallel plate perfusion chambers. The arrangement of the entire blood flow system is illustrated in Fig. 2 Fig. 2 ). In the remaining three tubings, the blood flowed in parallel at a rate of ml/min into a mixing device consisting of three individual mixing chambers. The blood flow was cc individual roller pumps positioned at the distal end or perfusion devices. Immediately before entering the X the flowing blood was supplemented with inhibitor sc 50 yl/min, resulting in a final concentration of 5% i inhibitors dissolved in 0.9% NaCl/0.1% BSA were s 1-ml glass syringes (Hamilton; Hamilton Bonadu; Switzerland) via an infusion pump (Infu 362; Datex A The inhibitors were mixed with the blood in tl chambers, each containing a rotating magnetic stir 1 homogenous blood/inhibitor mixture then entered ti perfusion devices (3) containing the endothelial cellThe blood flow of 1 ml/min resulted in a shear rate endothelial monolayer, which corresponded to venou ditions (4) . The second mixing device at the outlet chambers ( Fig. 2) was used only when additional I (FPA) determinations were carried out (see below). F metrical measurements of fibrin and for morphometr was connected directly to the three roller pumps. After sion period, the M199 wash solution reservoir was c distribution block without interrupting the flow. D washing period, the inhibitor infusion of 50 Ml/min i Then the mixing device was disconnected from the X vices, which were subsequently perfused at I ml/min ft paraformaldehyde in PBS (for immunochemical stain interruption of flow (-5 s). For morphometrical ex coverslips were perfused at 1 ml/min for 2 min with hyde in 0.1% cacodylate buffer, pH 7.4, containing 2. )ntrolled by three netic stirrer (Fig. 3) . The mixing device produced homogenous mixing fthe parallel plate as assessed by mixing a concentrated phenol red solution into human mixing chambers, plasma flowing at 1 ml/min into the parallel plate perfusion device.
)lution at a rate of The chamber volume was 37 mm3 (stir bar volume subtracted), which in the blood. The resulted in a turnover of 2.2 chamber volumes per second at a blood supplied by three flow rate of I ml/min.
z AG, Bonaduz, Determination of FPA levels. FPA levels were measured in the iG, Switzerland).
blood leaving the perfusion device (postchamber). A second mixing he three mixing device was positioned at the distal end of the parallel plate perfusion bar (Fig. 3) . The chambers (Fig. 2 ). This second mixing device served to mix the blood iree parallel plate with an anticoagulant cocktail (32 mg/ml trisodium citrate, 1,000 IU/ coated coverslips. ml heparin, and I TIU/ml aprotinin) to prevent further FPA generaof 65 s-' on the tion. The anticoagulant cocktail was supplied by an additional roller is blood flow conpump at a flow rate of 0.1 ml/min, resulting in a mixing ratio of 1:10 of the perfusion (anticoagulant cocktail/blood). The blood flow rate at the distal end of fibrinopeptide A the mixing device was 1.1 ml/min, which resulted in a blood flow rate or microdensitoof I ml/min (shear rate 65 so') over the endothelial cell layer consisy, the blood flow tent with the perfusion experiments described above. The anticoagu-'a 3.5-min perfu- (38) . The semithin sections were stained with 0.01% tolumixing of the idine blue and 0.01% fuchsin, and the deposition of platelets, fibrin, nhanced by and leukocytes along the length (8 mm) of the semithin section was driven by a determined morphometrically using a standard microscope (Carl Zeiss AG). Fibrin coverage was quantified by determining the presence or absence of fibrin at 10-tom intervals along the cross section (38) . This quantification method accurately reflects the amount of deposited fibrin as demonstrated by a parallel immunochemical quantification of fibrin, measuring fibrin fragment E after plasmin digestion (39) . The platelet aggregates and leukocytes were quantified by counting their number along the cross section. Platelet aggregates were defined as three or more cohesive platelets which underwent shape change and were in contact with fibrin, the HUVEC surface, or leukocytes. The total number of leukocytes adhering to fibrin, platelets, or directly to the HUVEC surface was determined along the total length ofthe cross section (8 mm). Because the length of cross sections varied slightly between the specimens, the number of leukocytes and platelets was normalized to a standard length of 10 mm.
Microdensitometry of immunogold-silver-stainedfibrin. After the perfusion experiments, the coverslips were processed for microdensitometrical fibrin determination as described recently (32 
Results
Minimal activation ofblood coagulation by the mixing device. The mixing device (Fig. 3) permitted a homogenous mixing of inhibitor with the flowing native blood. The activation ofblood coagulation because of the mixing was assessed by measuring the FPA levels in the blood leaving the mixing device. The average FPA levels from the blood of five donors was 6.8±0.8 ng/ml (±SEM). The activation of blood during the passage through the entire perfusion system consisting ofmixing device and perfusion chamber with uncoated cover slip (Fig. 2) was 8.6±4.1 ng/ml (±SEM; four donors). In accordance with this relatively low activation, no fibrin was detected on uncoated cover slips by fibrin-specific immunogold-silver staining.
Inhibition offibrin deposition on endothelial cells by thrombin inhibitors. Before the perfusion experiments, the endothelial cells were stimulated for 4 h with 2 nM TNF-a. This led to endothelial cell expression of tissue factor, resulting in fibrin deposition in the native blood flow system. To study the effect of the three thrombin inhibitors on fibrin deposition, the substances were infused into the flowing blood at a ratio of 1:20 by the mixing device before the blood entered the parallel plate perfusion devices containing the stimulated endothelial cells (Fig. 2) . Controls received 0.9% NaCl solution containing 0.1% BSA instead of inhibitor. We found that all three substances inhibited fibrin deposition on the endothelial cell monolayer in a concentration-dependent manner as determined by microdensitometry of immunogold-silver-stained fibrin (Fig.  4) . As expected, rec. hirudin was more potent than Ro 46-6240 and heparin (Fig. 4, inset (Fig. 6 b) . In contrast, leukocyte deposition was unaffected by the inhibitors (Fig. 6 c) . Representative cross sections in Fig. 7 illustrate that, in the presence of inhibitors, leukocytes adhered directly to the endothelial cell layer. In comparison, the surface of nonstimulated endothelial cells was free of thrombus constituents (Fig. 7 a) , whereas TNF-a-stimu- lated control cells were covered with fibrin, platelets, leukocytes, and red blood cells (Fig. 7 b) .
Focal deposition offibrin on endothelial cells at high inhibitor concentrations. Microscopical examination revealed that increasing concentrations of Ro 46-6240 reduced the fibrin deposition on endothelial cells almost completely. However, some residual fibrin formed locally, covering a few endothelial cells and apparently even single cells (Fig. 8, c and d) . This focal fibrin deposition may be related to the local fibrin accumulation seen on TNF-a-stimulated endothelial cells in the absence of inhibitor (Fig. 8 b) . Fig. 8 , e and ffurther illustrate single or several TNF-a-stimulated endothelial cells covered with stained fibrin fibers formed in the presence of the highest concentration ofRo 46-6240 (560 ng/ml). Similar results were obtained with the highest concentrations of rec. hirudin and heparin (data not shown). These results suggested that TNFa-stimulated endothelial cells express varying procoagulant activity. TNF-a-induced surface expression and distribution oftissuefactor on endothelial cells. To examine whether this inhomogenous distribution of procoagulant activity was related to the local density of endothelial tissue factor, we analyzed the surface expression oftissue factor by immunogold-silver staining. Fig. 9 shows the expression pattern of tissue factor on the surface of TNF-a-stimulated endothelial cells. The amount of tissue factor expressed by each cell varied strongly (Fig. 9, cand  d) . Tissue factor was not detectable on nonstimulated cells (Fig. 9, a and b) , which agrees with the findings from the perfusion experiments demonstrating that fibrin deposition was virtually absent on nonstimulated endothelial cells (Fig. 8 a) . Microscopical examination of TNF-a-stimulated endothelial cells by phase contrast combined with epifluorescence at a higher magnification more clearly visualizes the localization of tissue factor on each single cell (Fig. 9 g ). Similar results were obtained when another monoclonal antitissue factor antibody was used (monoclonal antibody 4507; American Diagnostica Inc.) (data not shown). The staining was specific since a control antibody did not produce any staining on TNF-a-stimulated cells (Fig. 9, e andf) . Since we used a pool ofendothelial cells from several umbilical cords, the inhomogenous tissue factor expression might have reflected variations of the different cord sources. Therefore, endothelial cells were isolated from single umbilical cords and examined at passage one in two separate experiments. Similar to the experiments with endothelial cells from pooled cords, we found varying degrees of tissue factor expression (data not shown).
Because human endothelial cells have two types of TNF-a receptors (30) , TNFR-p55 and TNFR-p75, we examined whether both receptors were involved in the TNF-a-depena no TNF-alpha Leukocytes (number/10 mm cross section) Figure 6 . Quantification of fibrin, platelets, and leukocytes deposited on TNF-a-stimulated endothelial cells. After exposure to flowing native human blood supplemented with either Ro 46-6240 (560 ng/ ml), rec. hirudin ( 140 ng/ml), or heparin ( 13,300 ng/ml), the endothelial cell-covered coverslips were processed for morphometrical analysis as described in Methods. Cross sections were stained with fuchsin/toluidine blue. dent heterogenous surface expression of tissue factor. To activate only one of the two receptors, we used mutated forms of human TNF-a with high selectivity for one receptor subtype (37) . Endothelial cells at first passage derived from a single cord were incubated with 2 nM of the TNFR-p55-selective mutant. This resulted in the upregulation oftissue factor which was detected by immunogold-silver staining using the tissue factor antibody HTFI-7B8 (Fig. 10 a) . The surface expression was heterogenous and similar to the experiments with wildtype TNF-a (Fig. 9 c) . In contrast, stimulation even with a high concentration ( 100 nM) ofthe TNFR-p75-selective mutant did not lead to any detectable surface expression of tissue factor (Fig. 10 b) , similar to the result with nonstimulated endothelial cells (Fig. 10 c) . The same results were obtained 2078 Kirchhofer, Tschopp, Hadvary, and Baumgartner '-I A oftissue factor expression using wild-type and mutated TNF-a forms suggested a relationship between the focal fibrin deposition and high local tissue factor density on the endothelial surface. The use of native blood in the experimental flow system averted interference with the coagulation system that occurs when using citrated or heparinized blood. This was particularly important for examining the anticoagulant activity of thrombin inhibitors. To supplement the native blood with inhibitor, a mixing device was developed which produced a homogenous blood/inhibitor mixture under steady flow conditions. The activation of the coagulation system in the mixing device as assessed by the FPA levels was < 1% ofpeak FPA levels observed with stimulated endothelial cells and did not result in any detectable fibrin deposition on uncoated cover slips.
At a shear rate of 65 s-', representing flow conditions in veins, the three thrombin inhibitors Ro 46-6240, rec. hirudin, and heparin inhibited fibrin formation, as assessed by FPA levels, by fibrin coverage determined on cross sections, and by density measurements after fibrin staining. On a molar basis rec. hirudin, as expected, was the most potent inhibitor. However, because of its low molecular weight, Ro 46-6240 was almost as active as rec. hirudin when the IC50 values were compared on a clinically relevant weight basis. In addition to their inhibitory effect on fibrin formation, rec. hirudin, and heparin also inhibited deposition of platelet aggregates on the endothelial surface. This was most likely because ofinhibition of the thrombin-mediated deposition of fibrin, the adhesive surface required for platelet deposition. In support of a fibrin-dependent platelet adhesion, we found that only 5% ofall platelet aggregates were in direct contact with the endothelial cells by a possible fibrin-independent mechanism. In contrast to the effect on fibrin and platelets, the thrombin inhibitors failed to prevent leukocyte adhesion. This agrees well with the findings from a similar blood flow system showing that leukocyte adhesion to TNF-a-stimulated endothelial cells persisted despite complete inhibition ofendothelial cell-mediated coagulation using antitissue factor antibody (32) . Leukocytes that adhered to the endothelial surface independent of thrombin and fibrin most likely interacted directly with upregulated leukocyte adhesion receptors on the endothelial surface (40) (41) (42) (43) .
The fibrin deposited on TNF-a-stimulated endothelial cells consisted of a fiber network and small and large fibrin accumulations (Fig. 8 b) . It was unclear why fibrin was deposited in such an irregular pattern. We hypothesized that some endothelial cells may express more procoagulant activity than others. In support of this we found residual fibrin that was deposited focally on stimulated endothelial cells in the presence ofhigh concentration ofthrombin inhibitors (Fig. 8, (Fig. 8   c) , suggesting that these fibrin deposits may be related to the dense fibrin accumulations that were found in the absence of inhibitor. Because tissue factor was the primary initiator ofthe coagulation process in this experimental system, we examined whether this apparently inhomogenous distribution ofprocoagulant activity on the endothelial surface was related to tissue factor distribution. Immunogold-silver staining of TNF-astimulated cells showed that the amount of surface-expressed tissue factor varied strongly from cell to cell, resulting in a heterogenous distribution pattern on the endothelial monolayer. This agrees well with the observed tissue factor heterogeneity in endotoxin-treated endothelial cells (27) , although that study (27) did not specify whether tissue factor was expressed on the cell surface. That our finding ofa heterogenous endothelial surface expression of tissue factor may have physiological relevance is suggested by the finding of Drake et al. (27) , demonstrating that tissue factor is heterogenously expressed in vascular beds of baboons exposed to E. coli. Although the reason for heterogeneity remains unclear, the results suggest that the varying degree oftissue factor expression may result in an inhomogenous procoagulant surface, leading to focal fibrin deposition in the native blood flow system.
In addition, since endothelial cells express two types of receptors for TNF-a, TNFR-p55 and TNFR-p75 (30) , it was important to find out whether both receptor types were involved in the heterogenous expression of tissue factor. Receptor-specific mutants of TNF-a were used to separately stimulate the receptor subtypes on the endothelial cells. The results clearly showed that tissue factor expression is regulated exclusively by TNFR-p55. Further, selective activation of TNFRp55 led also to a heterogenous tissue factor distribution on the endothelial surface. In contrast, the TNFR-p75-selective mutant did not lead to any detectable expression of tissue factor, even when used at high concentrations to compensate for the slightly lower affinity of this mutant for TNFR-p75 (37) . The finding of a TNFR-p55-dependent upregulation of tissue factor agrees well with the function ofthis receptor on endothelial cells to induce expression ofleukocyte adhesion receptors, such as E-selectin, intracellular adhesion molecule-1, and VCAM-1 (30, 31 ) . Thus, it appears that molecules that may play an important role in inflammation and disseminated intravascular coagulation are all regulated by TNFR-p55.
Therefore, a possible explanation for the heterogenous tissue factor distribution may be that TNFR-p55 is distributed heterogenously over the endothelial cell layer. In addition, individual cells could have been in different phases ofthe cell cycle, which might affect tissue factor expression as suggested by Andoh et al. (44) . Alternatively, independent of tissue factor expression, the endothelial cells might show variable procoagulant activity because they differ in the number or in the activity of their binding sites for the coagulation Factors IX and X (45) (46) (47) .
The tissue factor staining was localized on the apical surface In conclusion, our results suggest that the TNFR-p55-induced heterogenous surface expression of tissue factor may be linked to the observed heterogenous fibrin deposition on endothelial cells. When exposed to flowing native blood, areas on the endothelial monolayer with high tissue factor density might generate high local concentrations of thrombin. Despite the presence ofthrombin inhibitors at concentrations which significantly inhibit FPA generation, local fibrin deposition may occur. The results further showed a better activity of Ro 46-6240 in inhibiting fibrin deposition as compared with heparin. Together with the finding that it also inhibits clot-bound thrombin more potently than heparin (Gast, A., T. B. Tschopp, G. Schmid, K. Hilpert, and J. Ackermann, manuscript submitted for publication), Ro 46-6240 may show improved antithrombotic activity in vivo as compared with heparin, which is commonly used to treat venous thrombosis. In addition to the experiments with endothelial cells, this experimental blood flow system has broad applications in studying thrombotic processes. Dependent on the chosen thrombogenic surface and the shear rate, it permits one to investigate thrombotic processes under venous and arterial flow conditions in the presence of a given substance. Such studies may further elucidate processes that lead to thrombus formation under physiological and pathological conditions.
